Antibody Drug Conjugate News and Research

RSS

A new era of targeted therapy with antibody–drug conjugates

TBC

From Sino Biological Inc. 16 Dec 2024

New study unveils why glioblastoma becomes resistant to treatment

A new study from scientists at the UCLA Health Jonsson Comprehensive Cancer Center helps explain why glioblastoma, one of the most aggressive forms of brain cancer, becomes resistant to treatment, and introduces a new approach that paves the way for more personalized treatment strategies for patients with this deadly brain tumor.

22 Nov 2024

Advances in bladder cancer treatments offer hope for curative care

Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk localized, muscle-invasive disease, according to an editorial published in the New England Journal of Medicine.

14 Nov 2024

New combination treatment authorized for unresectable urothelial cancer patients

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in combination with KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer, who are eligible for platinum-containing chemotherapy.

18 Oct 2024

New drug could extend the lives of breast cancer patients

LMU researchers have successfully tested a new drug which can significantly extend the lives of breast cancer patients.

4 Oct 2024

ESMO 2024: Promising results in immunotherapy and antibody drug conjugates for gynecological cancers

Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found 'promising' antitumor activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers.

16 Sep 2024

Antibody-drug conjugate shows promise in treating ovarian and endometrial cancers

14 Sep 2024

New cancer drug shows encouraging results in Phase I/II trial

The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with advanced or metastatic solid tumors, according to interim data shared today at the 2024 European Society for Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.

14 Sep 2024

New drug shows strong activity against brain metastases in HER2-positive breast cancer

A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2-positive breast cancer.

13 Sep 2024

Telisotuzumab vedotin shows promising results in asian patients with c-Met overexpressing NSCLC

The c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptable safety profile in patients of Asian race with c-Met protein-overexpressing, epidermal growth factor receptor (EGFR) wildtype (WT), locally advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC), according to research presented today at the International Association for the Study of Lung Cancer's 2024 World Conference on Lung Cancer.

11 Sep 2024

A novel therapeutic option for HER2-positive extramammary Paget disease

The research article presents a comprehensive evaluation of the human epidermal growth factor receptor 2 (HER2) status in extramammary Paget disease (EMPD) and explores the therapeutic potential of disitamab vedotin (DV), a novel humanized anti-HER2 antibody-drug conjugate (ADC), for this rare adenocarcinoma.

4 Sep 2024

New advances in Hodgkin's lymphoma treatment offer hope for affected individuals

Hodgkin's lymphoma (HL), impacting the lymph nodes and lymphatic system, has experienced a gradual increase in survival rates thanks to contemporary chemotherapy.

13 Aug 2024

Drug shows new promise in treating breast cancer with brain metastases or recurrent glioblastoma

A drug effective in treating breast cancer shows new promise in addressing breast cancer with brain metastases or recurrent glioblastoma, as reported by results of a prospective window-of-opportunity trial at the University of Texas Health Science Center at San Antonio (UT Health San Antonio).

8 Aug 2024

New treatment option for endometrial cancer shows promise in phase II trial

The latest trial of a new antibody drug that delivers potent chemotherapy directly to cancer cells for patients with advanced or recurrent endometrial cancer moves ahead to be studied further in a phase III trial.

1 Aug 2024

Antibody-drug conjugate shows preclinical efficacy

A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, "Entering the golden age for antibody-drug conjugates in gynecologic cancer."

13 Jul 2024

Antibody-drug conjugate effective, less toxic for stage 1 HER2+ breast cancer

A year of treatment with a medicine made of an antibody and chemotherapy drug has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients, a team led by Dana-Farber Cancer Institute researchers has found.

28 Jun 2024

Tailored antibody-drug conjugate offers hope for aggressive breast cancer

Scientists have used breast cancer cells' weakness against themselves by linking a tumour-selective antibody with a cell-killing drug to destroy hard-to-treat tumors.

21 May 2024

Novel vaccine approach targets AML and other blood cancers

Acute myeloid leukemia (AML) is a type of blood cancer that forms in the soft marrow of the bones, typically attacking cells that would otherwise form the key component of the body's immunodefense system, white blood cells.

3 May 2024

First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer

The real-world safety and efficacy of sacituzumab govitecan (SG) against metastatic triple-negative breast cancer.

26 Apr 2024

Research reveals potential target for enfortumab vedotin therapy in urothelial carcinoma

Under the leadership of PD Dr. Niklas Klümper, Assistant Physician at the Department of Urology at the University Hospital Bonn (UKB) and Clinician Scientist of the BMBF-funded ACCENT program and PD Dr. Markus Eckstein, senior physician at the Institute of Pathology at the Uniklinikum Erlangen of the Friedrich-Alexander-University Erlangen-Nürnberg (FAU), an interdisciplinary research team has published new findings that indicate which patients with advanced urothelial carcinoma could benefit in particular from the new targeted therapy with the antibody-drug conjugate enfortumab vedotin.

24 Apr 2024